EP Patent

EP2899207A1 — New method for testing HCV protease inhibition

Assigned to AmikanaBiologics · Expires 2015-07-29 · 11y expired

What this patent protects

The present invention relates to a vector coding for an antitoxin comprising a nucleic acid sequence under the control of a promoter, wherein (i) said nucleic acid sequence encodes a pro-antitoxin comprising the sequence of a cleavage site of a HCV protease, and (ii) said pro-ant…

USPTO Abstract

The present invention relates to a vector coding for an antitoxin comprising a nucleic acid sequence under the control of a promoter, wherein (i) said nucleic acid sequence encodes a pro-antitoxin comprising the sequence of a cleavage site of a HCV protease, and (ii) said pro-antitoxin has to be cleaved by said HCV protease to be activated; a cell transformed by such a vector, a method using such transforming cell for testing the ability of a compound to inhibit a HCV protease; and a kit for testing the ability of a compound to inhibit HCV protease.

Drugs covered by this patent

Patent Metadata

Patent number
EP2899207A1
Jurisdiction
EP
Classification
—
Expires
2015-07-29
Drug substance claim
No
Drug product claim
No
Assignee
AmikanaBiologics
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.